Astellas has signed an R&D and licensing deal with Kelonia Therapeutics that aims to develop CAR-T therapies for cancer that will push the boundaries of what can be achieved with the technology.
The $800 million agreement between Keonia and Astellas’ Xyphos Biosciences subsidiary is designed to address three limitations with the current generation of CAR-Ts.
